公告称，业绩增长主要来自核心品牌的强劲销售表现，尤其是品牌药分部的何济公及品牌中药分部的保 济丸，得益于专注的品牌管理及有效的市场推广执行。集团的中药配方颗粒业务亦表现稳定，为品牌健 康业务组合作出持续贡献。 消息面上，健倍苗苗公布截至2025年9月30日止6个月中期业绩，收益约为4.3亿港元，同比增加约 7.7%；公司权益持有人应占溢利约为1.15亿港元，同比增加约20.0%；每股盈利14.12港仙，中期股息每 股普通股9.75港仙。 健倍苗苗(02161)涨超5%，截至发稿，涨5.19%，报3.04港元，成交额155.88万港元。 ...

公告称，业绩增长主要来自核心品牌的强劲销售表现，尤其是品牌药分部的何济公及品牌中药分部的保 济丸，得益于专注的品牌管理及有效的市场推广执行。集团的中药配方颗粒业务亦表现稳定，为品牌健 康业务组合作出持续贡献。 消息面上，健倍苗苗公布截至2025年9月30日止6个月中期业绩，收益约为4.3亿港元，同比增加约 7.7%；公司权益持有人应占溢利约为1.15亿港元，同比增加约20.0%；每股盈利14.12港仙，中期股息每 股普通股9.75港仙。 智通财经APP获悉，健倍苗苗(02161)涨超5%，截至发稿，涨5.19%，报3.04港元，成交额155.88万港 元。 ...

公告称，业绩增长主要来自核心品牌的强劲销售表现，尤其是品牌药分部的何济公及品牌中药分部的保 济丸，得益于专注的品牌管理及有效的市场推广执行。集团的中药配方颗粒业务亦表现稳定，为品牌健 康业务组合作出持续贡献。 健倍苗苗(02161)公布截至2025年9月30日止6个月中期业绩，收益约为4.3亿港元，同比增加约7.7%。公 司权益持有人应占溢利约为1.15亿港元，同比增加约20.0%。每股盈利14.12港仙，中期股息每股普通股 9.75港仙。 ...

智通财经APP讯，健倍苗苗(02161)公布截至2025年9月30日止6个月中期业绩，收益约为4.3亿港元，同 比增加约7.7%。公司权益持有人应占溢利约为1.15亿港元，同比增加约20.0%。每股盈利14.12港仙，中 期股息每股普通股9.75港仙。 公告称，业绩增长主要来自核心品牌的强劲销售表现，尤其是品牌药分部的何济公及品牌中药分部的保 济丸，得益于专注的品牌管理及有效的市场推广执行。集团的中药配方颗粒业务亦表现稳定，为品牌健 康业务组合作出持续贡献。 ...

Core Viewpoint - The article highlights significant movements in the Hong Kong and US stock markets, driven by geopolitical tensions, corporate earnings, and strategic partnerships, indicating potential investment opportunities and sector performance trends. Group 1: Hong Kong Stock Market Highlights - Gold stocks opened high due to rising geopolitical tensions in the Middle East, with gold prices surpassing $3,400 [1] - Chow Tai Fook (01929) rose over 7% post-earnings, with Morgan Stanley raising its target price by 7.7% to HKD 14, reflecting better-than-expected fiscal 2025 results and a continued demand recovery [1] - Eucure Biopharma-B (01477) increased over 6% after receiving approval for its OT-802 Phase III clinical trial in China [1] - Television Broadcasts (00511) surged over 12% following partnership agreements with Tencent Video, Shenzhen Satellite TV, Huawei, and iFlytek [1] - Four Seasons Pharmaceutical (00460) rose over 4% as its new drug application for Pyrotinib was officially accepted by NMPA [1] - Jianbei Miao Miao (02161) increased over 6% with a 51.2% year-on-year growth in net profit, attributed to strong performance from flagship brands [1] - ConvaTec-B (02162) fell over 6% due to a discounted share placement raising over HKD 850 million, with the controlling shareholder reducing their stake [1] Group 2: Sector Performance and Trends - Shipping stocks rose against the trend, with Cosco Shipping Energy (01138) up over 10%, influenced by ongoing geopolitical crises affecting the Red Sea [2] - Automotive stocks declined across the board, with Xpeng Motors dropping over 5% amid potential tariff increases on vehicles [2] - Shandong Molong (00568) surged over 60% as oil prices spiked over 10% due to heightened geopolitical risks [2] - Innovative drug concept stocks faced significant declines, with several biotech companies experiencing a wave of share placements [2] - North Sea Kangcheng-B (01228) rose over 31% after receiving approval for its injectable drug [2] - Delin International (01126) increased over 10%, with positive outlooks for the toy market [2] Group 3: US Stock Market Highlights - Boeing (BA.US) fell 4.81% following the first accident involving its 787 aircraft [3] - CureVac (CVAC.US) surged over 37% after BioNTech announced a $1.25 billion acquisition to enhance its cancer business [3] - Oracle (ORCL.US) rose 13.25% as it projected over 70% growth in cloud infrastructure sales [3] - Adobe (ADBE.US) initially rose over 6% but later fell over 1%, reporting Q2 revenue of $5.87 billion, exceeding analyst expectations [3] - MP Materials (MP.US) rose over 8% after receiving funding from the Department of Defense for rare earth projects [4] - Chime (CHYM.US) saw a 37% increase on its IPO day, signaling a revival in the fintech IPO market [4]